ClinicalTrials.gg
CompletedNCT00870103Updated Mar 9, 2010Results posted

Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery

A Phase 4 interventional study of Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops in Cataract, sponsored by Alcon Research. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-03-09.

Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
64
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing moxifloxacin in Cataract — 1 open to participants now, 1 under way, 1 of them phase 3. Moxifloxacin · Cataract.

Enrollment
6th of 12
64 · median 62
Started
2008
with 1 other
Phase 4
9 of 12
none open now
Registered
2nd of 12
by date
Lead sponsor
4 of 12
Alcon Research

Among the 12 studies testing moxifloxacin in Cataract, this one is the 6th largest by enrollment, is one of 2 that started in 2008, is one of 9 in phase 4, and was the 2nd registered.

Cataract

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

1 of the 12 studies testing moxifloxacin in Cataract is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About moxifloxacin

Moxifloxacin: first FDA approval 1999 (AVELOX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing moxifloxacin in Cataract, or all of them as a file.
02

Study summary

To demonstrate that the combination formulation of Moxifloxacin/Dexamethasone Eye Drop is effective and safe for the prevention of postoperative inflammation as a consequence of cataract extraction surgery.

03

Conditions studied

  • Cataract

Browse trials for

Keywords

  • Cataract
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≧18 years of age
  • able to sign an and complete all required visits
  • intends to have a cataract extraction surgery followed by implantation of a posterior chamber Intraocular lens (IOL)
  • Intraocular Pressure (IOP) ≦ 20 millimeters mercury (mmHg)

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled glaucoma or IOP
  • use of ocular anti-infectious during the study and within 30 days prior to the enrollment, secondary implantation or replacement of IOL in the study eye
  • use of during the study or within 14 days prior to enrollment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Vigadexa eye drops

    Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops

    Drug: Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops

Interventions

  • DrugVigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops

    Drug page: Moxifloxacin

    1 drop every 6 hours into the study eye

06

What researchers measure

Primary outcomes

  1. The Percentage of Patients With a Score of Zero for Anterior Chamber Cells.

    The percentage of patients with a score of zero for Anterior chamber cells. Anterior chamber inflammation was evaluated based on the number of cells per high-power field measured using the narrowest slit beam of the lamp (0.5 at a height of 8mm). Anterior chamber cells was recorded on a 0-4 point scale,0 = Less than 5 cells; 1 = Mild: 5-10 cells; 2 = Moderate:11-20 cells; 3 = Marked: 21-50 cells; 4 = Severe: Greater than 50 cells / hypopyon

    Time frame: Day 15 after cataract surgery

  2. The Percentage of Patients With no Ocular Pain

    Time frame: Day 15 after cataract surgery

07

Results

Posted Feb 15, 2010

Participant flow

64 patients were enrolled into the study

Participant flow — Overall Study
MilestoneVigadexa Group
Started64
Completed60
Not completed4
Withdrew: Physician decision2
Withdrew: Lost to follow-up2

Outcome measures

PrimaryThe Percentage of Patients With a Score of Zero for Anterior Chamber Cells.

The percentage of patients with a score of zero for Anterior chamber cells. Anterior chamber inflammation was evaluated based on the number of cells per high-power field measured using the narrowest slit beam of the lamp (0.5 at a height of 8mm). Anterior chamber cells was recorded on a 0-4 point scale,0 = Less than 5 cells; 1 = Mild: 5-10 cells; 2 = Moderate:11-20 cells; 3 = Marked: 21-50 cells; 4 = Severe: Greater than 50 cells / hypopyon

Time frame:
Day 15 after cataract surgery
Reported as:
Number · Percentage of participants
The Percentage of Patients With a Score of Zero for Anterior Chamber Cells.
Percentage of participantsVigadexa Group
The Percentage of Patients With a Score of Zero for Anterior Chamber Cells.91.7
PrimaryThe Percentage of Patients With no Ocular Pain
Time frame:
Day 15 after cataract surgery
Reported as:
Number · Percentage of participants
The Percentage of Patients With no Ocular Pain
Percentage of participantsVigadexa Group
The Percentage of Patients With no Ocular Pain96.7

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vigadexa Group—0/64 (0%)0/64 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Vigadexa Group
<=18 years0
Between 18 and 65 years21
>=65 years43
Sex: Female, Male
Sex: Female, Male(Participants)Vigadexa Group
Female37
Male27
08

Study locations

1 site
  • Alcon Call Center
    Fort Worth, Texas 76134, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008 and a primary completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2008
First posted
Mar 26, 2009
Start
Sep 2008
Primary completionActual
Feb 2009
Results first posted
Feb 15, 2010
Last update
Mar 9, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00870103
Lead sponsor
Alcon Research
First posted
Mar 26, 2009
Start date
Sep 2008
Primary completion
Feb 2009
Results posted
Feb 15, 2010
Last update
Mar 9, 2010

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion